Bio-Techne (TECH) Supports Sonoma Biotherapeutics with $300K G-Rex® Grant for Gene Therapy

Bio-Techne Advances Gene Therapy Manufacturing with G-Rex® Grant for Sonoma Biotherapeutics

In a significant development for the biotechnology sector, Bio-Techne Corporation, in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, plays a pivotal role in awarding a $300,000 G-Rex® Grant to Sonoma Biotherapeutics. This grant aims to enhance the manufacturing process for gene-modified regulatory T cell (Treg) therapies, which are expected to revolutionize treatment options for autoimmune disorders. The initiative marks a crucial shift from traditional open flask technology to the more efficient and commercially viable G-Rex platform, which promises to streamline the production of these advanced therapies.

John Wilson, the CEO of Wilson Wolf and co-inventor of the G-Rex technology, highlights that the grant is instrumental in transitioning Sonoma Biotherapeutics towards a scalable and modular manufacturing approach. By leveraging the G-Rex platform, SonomaBio can implement innovative optimization strategies that will not only enhance the efficacy of their Treg therapies but also prepare them for clinical trials. The integration of closed system G-Rex devices and ProPak™ GMP Cytokines stands to improve the consistency and reliability of the manufacturing process, which is essential for meeting the stringent demands of regulatory compliance in the biopharmaceutical industry.

Additionally, the G-Rex Grant Program, spearheaded by ScaleReady, has reached an impressive milestone, totaling over $40 million in no-cost product commitments aimed at supporting the development of cell and gene-modified therapies (CGT). This financial backing enables companies like SonomaBio to access exclusive resources and support, including guidance on cGMP manufacturing and regulatory affairs. In tandem with this initiative, ScaleReady has introduced the LEAN Cell & Gene™ program, developed in partnership with Hanson Wade, to further assist CGT entities in enhancing manufacturing efficiency and quality through a series of complimentary events and workshops.

In summary, Bio-Techne's involvement in the G-Rex Grant Program exemplifies the company's commitment to advancing the biotechnology landscape. By supporting innovative firms like Sonoma Biotherapeutics, Bio-Techne not only facilitates the development of critical therapeutic solutions for autoimmune diseases but also strengthens its position as a leader in the biomanufacturing sector.

As the biotechnology industry continues to evolve, initiatives such as the G-Rex Grant Program and the LEAN Cell & Gene™ series are crucial for fostering collaboration and innovation among key players. Interested parties are encouraged to reach out to ScaleReady for further information on these valuable resources and opportunities.